ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Cytokines and cognitive function in first-episode drug-naïve MDD: an inflammation panel perspective.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Inflammation is involved in the process of cognitive impairment in some psychiatric disorders; however, the relationship between cognitive function and inflammation markers in major depressive disorder (MDD) remains unclear. Herein, we sought to investigate the alterations in cytokine levels and the relationships between cytokine levels and cognitive performance in MDD patients and healthy controls (HCs) from the perspective of the inflammation panel. This present study included 170 participants, including 101 first-episode drug-naïve MDD patients and 69 HCs. The levels of 27 cytokines were assayed by the Bio-Plex human 27-plex (BioRad). The depressive and anxiety symptoms were evaluated using the Hamilton Depression Rating Scale-17 (HAMD-17) and Hamilton Anxiety Rating Scale-14 (HAMA-14), respectively. The cognitive function was assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Toronto Alexithymia Scale (TAS-20). First-episode drug-naïve MDD patients exhibited significantly poorer neurocognitive and social cognitive function compared to HCs, even after adjusting for potential confounders. Of the 27 cytokines measured, 26 were significantly elevated in MDD patients. The principal component analysis identified five components accounting for 71.26% of the variance, with four components differing significantly between the MDD and HC groups. Notably, PC3, comprising RANTES, IL-9, MIP-1beta, TNF-alpha, IL-2, and IL-10, demonstrated strong discriminative power between MDD and HCs (AUC = 0.829, 95%CI: 0.769-0.889). The analysis revealed that PC3 and its contained cytokines (RANTES, IL-9, IL-2, and IL-10) exhibited a negative correlation with the scores of TAS-20, RBANS, and its subscales in HCs, but no such associations were observed in MDD patients. Our findings may contribute to elucidating the biological mechanisms underlying cognitive impairment in MDD by emphasizing the relationship between cytokine subtypes, including RANTES, IL-9, IL-2, and IL-10, and cognitive functions.
Indexed as
Identifiers
41801436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.